China’s clampdown on polluting industrial units ahead of the Beijing Winter Olympics is raising the prices of active pharmaceutical ingredients (APIs) and key starting materials (KSMs), which along with concerns over the Omicron SARS-CoV-2 variant, could signal a perfect storm building for the pharma industry in the days and months ahead.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?